Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics tags : Iot save search
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting
Published: 2022-03-21 (Crawled : 13:30) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.0%
H: 0.06%
C: -4.79%
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: 2.03%
H: 0.66%
C: -5.96%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
cutx-101 america genetic therapeutics biotech iot
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease
Published: 2022-03-18 (Crawled : 11:00) - prnewswire.com
PLX | $1.15 1.77% -2.61% 450K
|
Health Services
|
| O: 6.44%
H: 11.11%
C: 6.06%
prx-102 treatment rare trial therapeutics disease results iot prx012
Stealth BioTherapeutics to Host Virtual Event on the Potential of Elamipretide in Treatment of Geographic Atrophy in Dry Age-Related Macular Degeneration
Published: 2022-03-17 (Crawled : 21:00) - prnewswire.com
MITO | $0.32 0.25%
|
Health Technology
|
| O: 0.0%
H: 8.2%
C: 8.2%
treatment therapeutics potential iot macular elamipretide
Stealth BioTherapeutics Showcases New Duchenne Muscular Dystrophy Nonclinical Data at the 2022 Muscular Dystrophy Association and Clinical and Scientific Conference
Published: 2022-03-16 (Crawled : 22:00) - biospace.com/
MITO | $0.32 0.25%
|
Health Technology
|
| O: 3.37%
H: 0.0%
C: -10.28%
muscular dystrophy conference therapeutics duchenne iot
Biotech Acquisition Company Announces Public Filing of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.
Published: 2022-03-16 (Crawled : 14:00) - biospace.com/
BIOT | $10.15 -0.78% -0.2% 44K
|
|
| O: 0.5%
H: 0.3%
C: 0.1%
acquisition pos state therapeutics biotech iot merge
Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis
Published: 2022-03-16 (Crawled : 12:00) - biospace.com/
PTGX | $25.61 1.55% 1.52% 450K
|
Health Technology
|
| O: 2.01%
H: 1.1%
C: 0.57%
pn-235 phase 2 phase 2b trial therapeutics psoriasis one biotech iot milestone plague
Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors
Published: 2022-03-16 (Crawled : 12:00) - biospace.com/
SONN | $1.84 3.96% 3.8% 22K
|
Health Technology
|
| O: 79.48%
H: 35.23%
C: 4.04%
son-1010 treatment fda clearance solid tumors therapeutics fda clearance iot
Iovance Biotherapeutics to Present at Upcoming Conferences
Published: 2022-03-16 (Crawled : 11:00) - globenewswire.com
IOVA | News M | $11.32 -3.41% -3.53% 5.3M
|
Health Technology
|
| O: 6.55%
H: 0.68%
C: 0.45%
conference therapeutics iot
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Published: 2022-03-15 (Crawled : 22:00) - globenewswire.com
IOVA | News M | $11.32 -3.41% -3.53% 5.3M
|
Health Technology
|
| O: 6.55%
H: 0.68%
C: 0.45%
therapeutics nasdaq report iot grant granted
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2022-03-14 (Crawled : 21:00) - arcutis.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 1.08%
H: 0.88%
C: 0.44%
therapeutics nasdaq report iot grant granted
Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights
Published: 2022-03-10 (Crawled : 12:30) - globenewswire.com
SNSE | $1.03 4.79% 4.57% 24K
|
|
| O: -1.22%
H: 4.02%
C: -6.19%
financial results therapeutics report results iot
Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors
Published: 2022-03-09 (Crawled : 23:00) - globenewswire.com
SNSE | $1.03 4.79% 4.57% 24K
|
|
| O: -1.22%
H: 4.02%
C: -6.19%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.02%
H: 1.86%
C: 1.21%
ASMB | $13.64 2.33% 2.27% 11K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.55%
air therapeutics iot
Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022
Published: 2022-03-08 (Crawled : 22:00) - globenewswire.com
BOLT | $1.12 -1.75% -1.79% 55K
|
|
| O: 3.38%
H: 13.07%
C: 11.44%
program therapeutics preclinical iot pre-clinical
Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
Published: 2022-03-08 (Crawled : 22:00) - globenewswire.com
IOVA | News M | $11.32 -3.41% -3.53% 5.3M
|
Health Technology
|
| O: 2.21%
H: 6.63%
C: 5.78%
america research therapeutics cancer iot
Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference
Published: 2022-03-03 (Crawled : 20:00) - biospace.com/
SNSE | $1.03 4.79% 4.57% 24K
|
|
| O: -1.49%
H: 3.86%
C: -3.93%
health thc conference therapeutics iot
SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations
Published: 2022-03-02 (Crawled : 12:00) - biospace.com/
SABS | $4.46 0.22% 890
|
|
| O: -14.32%
H: 0.0%
C: -33.17%
sab-185 covid-19 treatment trial therapeutics covid report phase 3 iot
SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants
Published: 2022-03-02 (Crawled : 01:00) - globenewswire.com
SABS | $4.46 0.22% 890
|
|
| O: -14.32%
H: 0.0%
C: -33.17%
sab-185 therapeutics sars-cov-2 iot
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
Published: 2022-02-28 (Crawled : 22:00) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: -0.61%
H: 1.41%
C: -1.98%
financial results ces therapeutics results iot
SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19
Published: 2022-02-25 (Crawled : 12:00) - biospace.com/
SABS | $4.46 0.22% 890
|
|
| O: 1.57%
H: 0.0%
C: 0.0%
sab-185 covid-19 treatment trial therapeutics covid phase 3 iot designation
Oncotelic Presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference
Published: 2022-02-24 (Crawled : 14:00) - globenewswire.com
OTLC | $0.042 -44.63% 100K
|
Manufacturing
|
| O: -2.04%
H: 6.38%
C: 6.38%
technology conference biotech iot
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.